Research Square
July 20, 2023
Orr Shahar, Alexander Botvinnik, Amit Shwartz et al.
3 citations
preprint
Abstract Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or “full spectrum” (psychedelic) mushroom extract (PME), may differ from those of chemically synthesized psilocybin (PSIL). We compared the...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
July 19, 2023
Kaden Venugopal
1 citation
Introduction: Major depressive disorder (MDD) is a prevalent and complex mood disorder. Its psychotherapies often involve delayed treatment-response times, while its pharmacotherapies can cause unwanted side effects. In recent years, there has been a resurgence in psychedelic research with a specific interest in the potential of psilocybin for treating MDD. Therefore, this systematic review was...
Psychological Medicine
July 19, 2023
Brandon Weiss, Induni Ginige, Lu Shannon et al.
1 citation
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
International Journal of Gynecological Cancer
July 18, 2023
Dan Yaniv, L. Ramondetta, L. Cohen et al.
Women with gynecologic cancers face various physical and psychological challenges throughout their treatment journey. Late stages associated with poor prognosis, along with chronic side effects of treatment, often leave women with existential uncertainty stemming from unpredictable disease trajectory and continuous fear of death. Recently, a patient in her late 30s (JN) with endstage ovarian...
Research Square
July 18, 2023
Sanah Malomile Nkadimeng, L. Hay, Christiaan Ml Steinmann et al.
1 citation
preprint
Abstract Background Psilocybin-containing mushrooms induce antidepressant and momentary increase in blood pressure (BP) with potential risk to users with cardiovascular diseases. Irregularities in nitric oxide (NO) levels play a key role in endothelial dysfunctions leading to increases in BP. Mushrooms species show large variation in potency which may potentially induce different outcomes and...
Journal of Affective Disorders
July 15, 2023
Matthew B. Wall, Cynthia Lam, Natalie Ertl et al.
36 citations
Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following PT. Brain responses to music were assessed before and after PT using...
Nature
July 13, 2023
Rich Haridy
55 citations
Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed. Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed.
British medical journal
July 11, 2023
B. Nogrady
18 citations
The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...
July 6, 2023
Jenny Tetem, Tamara Fischmann, Tim Julian Möller
preprint
This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of what opportunities and risks are associated with the use of the psychoactive substance psilocybin. Peer-reviewed studies between 2017 and 2022 were included. Nine studies were found regarding the following indications: tobacco addiction, anxiety and...
Current Topics in Medicinal Chemistry
July 6, 2023
Udoka C. Ezeaka, Hye Ji J. Kim, Robert B. Laprairie
1 citation
Abstract: Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. Pre-clinical investigation of these compounds in rodent models forms a key component of their drug development process. In this review, we will summarize the evidence...